scholarly journals Patient-Administered Biologic and Biosimilar Filgrastim May Offer More Affordable Options for Patients with Nonmyeloid Malignancies Receiving Chemotherapy in the United States: A Budget Impact Analysis from the Payer Perspective

2019 ◽  
Vol 25 (1) ◽  
pp. 94-101 ◽  
Author(s):  
Holly Trautman ◽  
Erika Szabo ◽  
Elizabeth James ◽  
Boxiong Tang
Sign in / Sign up

Export Citation Format

Share Document